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Abstract 
We report 2 patients with cold urticaria with different response to treatment with 
omalizumab (Xolair®). Cold contact urticaria (CCU) is a common subtype of physical urticaria. 
It is characterized by the development of wheal and/or angioedema within minutes after 
cold contact. Clinical manifestation of CCU can range from mild, localized whealing to life-
threatening anaphylactic shock reactions. Omalizumab has been described to be useful in 
cases of chronic urticaria and may be an interesting option for treatment of CCU. We 
describe one patient with significant and long-lasting improvement of symptoms and one 
without any improvement after anti-immunoglobulin E therapy. In our case reports, we want 
to highlight that there is still a small group of patients without benefit from omalizumab 
treatment. It is necessary to identify this minor subgroup of patients where omalizumab 
does not represent an effective treatment possibility. 
 
Introduction 
Cold contact urticaria (CCU) accounts for approximately 3% of all cases of chronic 
urticaria [1]. Among all physical urticarias, CCU represents the second most common 
subtype after symptomatic dermographism [2]. CCU is characterized by development of 
wheal and/or angioedema within minutes after cold contact. CCU patients are also at 
risk of anaphylaxis or oropharyngeal edema. Acquired CCU is mostly idiopathic or can 
be secondary in cryoglobulinemia, infectious diseases, etc. 
Current guidelines for the symptomatic treatment of CCU recommend a stepwise 
approach beginning with the classical dose of nonsedating H1-antihistamines (nsAHs), 
then increasing the doses of nsAHs up to 4-fold if symptoms persist before changing to 
a different nsAHs. In very severe cases also other therapeutic options such as 
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cyclosporin A or oral steroids might be used [3]. The goal of the treatment of urticaria 
is determined by complete symptom control. It has been previously shown that 
omalizumab treatment can be safe and effective in patients suffering from recalcitrant 
physical urticarias such as cold urticaria [4]. 
Case Reports 
We report different effects of anti-immunoglobulin E (IgE) therapy in 2 patients with cold contact 
urticaria, both nonresponsive to high doses of nsAHs. 
First Case Report 
A 53-year-old woman suffered from severe, treatment-refractory cold contact urticaria. Before 
anti-IgE treatment, the patient had been affected by recurrent itchy and painful rash in the face and 
other cold-exposed areas for 4 months. Raised, erythematous, intensely pruritic skin lesions typically 
developed within minutes after exposure to low temperatures, especially after contact with cold air or 
cool water. She did not tolerate ingestion of cold drinks and foods; she experienced itching of the lips 
and tongue. There were no associated symptoms, such as fever or arthralgia. Progressing symptoms 
limited her outdoor activities in the cold and also food choices. She has received several unsuccessful 
therapies, including various sedating and nonsedating antihistamines, and intermittent oral steroid 
treatments. Before anti-IgE treatment, cold provocation test was performed. An ice cube applied to 
the skin resulted in the development of massive wheal and redness within 3 min after removal. Her 
medical history included chronic hepatitis B. Hepatitis serological marker (anti-HBs) was positive. 
Furthermore, she had undergone surgery for urothelial cell carcinoma 6 years previously, and was 
currently without any urological problems. Other relevant concomitant diseases were excluded. No 
family members had cold-induced rashes. Before anti-IgE therapy was initiated, hte patient’s total IgE 
was 207 kU/l. The patient received a subcutaneous dose of 300 mg/month of omalizumab (added to a 
stable dose of H1-antihistamine). Omalizumab was administered according to the US Food and Drug 
Administration-approved dosing table for the treatment of asthmatic patients, determining the 
omalizumab dose by body weight and total IgE levels [5]. The patient reported significant 
improvement of symptoms already within 1 week after the first injection. Omalizumab was well 
tolerated, without any adverse effects. After 4 months with complete symptom control, anti-IgE 
therapy was stopped. At the last follow-up, 5 months after the last application of omalizumab, the 
patient is currently still free of symptoms. Cold provocation test did not lead to any development of 
urticarial rash. In case of recurrence of urticaria symptoms, we plan to restart anti-IgE therapy. 
Second Case Report 
A 30-year-old woman presented with severe cold intolerance with urticarial rash for 1 year. 
Symptoms were induced also by cold provocation test. Cold exposure was extremely disabling for her. 
The patient experienced diffuse urticaria with shortness of breath and dizziness occasionally. No 
evidence for an underlying disease (e.g. infection, cryoglobulinemia) was found. Her personal and 
family history was negative. Before anti-IgE therapy was initiated, the patient’s total IgE was 20.8 
kU/l. The patient did not respond to oral antihistamine treatment including 4-fold dosage. Therefore 
treatment with 300 mg omalizumab subcutaneously every 4 weeks was initiated. The patient 
repeatedly reported fatigue and somnolence all day long after administration of omalizumab. 
Unfortunately, anti-IgE therapy resulted in only incomplete symptom control. Due to adverse events 
and insufficient efficacy, omalizumab treatment was discontinued after 8 months. Cyclosporin A 
treatment was initiated with 200 mg daily, combined with H1-antihistamine. Due to headaches 
reported by the patient, the dosage of cyclosporin A was reduced to 150 mg daily. At the last follow-
up, the patient still has not achieved complete remission. The patient has also received an emergency 
kit with oral corticosteroid, antihistamine and an adrenaline injector. 
Discussion 
Cold contact urticaria accounts for approximately 3% of all cases of chronic urticaria 
[1]. Among all physical urticarias, CCU represents the second most common subtype 
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after symptomatic dermographism [2]. CCU is characterized by the development of 
wheal and/or angioedema within minutes after cold contact. Extensive cold contact of 
large areas of skin may lead to systemic reactions such as generalized urticaria, 
dyspnoea, tachycardia, hypotension and loss of consciousness [6]. Severe CCU has a 
significant impact on the patient’s quality of life both in a physical and psychological 
sense [7]. 
The onset of CCU symptoms may occur at any age but shows a peak in young adults 
and a weak predominance in women [6]. The symptoms of all physical urticarias are 
caused by the activation of mast cells and by their release of proinflammatory 
mediators. However, it is largely unknown how and why mast cells are activated in 
physical urticaria, i.e. which signals are responsible for mast cells activation [8]. 
Although no underlying causes are detectable in most CCU patients, an association of 
CCU with cryoglobulinemia, hematologic disorders has been described in a small subset 
of patients [9]. Also, a link between CCU and various viral, parasitic, or bacterial 
infections could be observed. Genomic deletions in PLCG2 were recently found in 3 
independent families with lifelong cold urticaria [10]. Wanderer et al. [6] proposed a 
classification scheme for cold urticaria based on the severity of reactions (table 1). 
It is important to note that anaphylactic reactions are very common in patients with 
cold urticaria. These occur most often during water immersion [11]. Patients who 
experience oropharyngeal reactions to cool liquids or foods (most commonly 
manifested as lip swelling) are said to be more likely to experience systemic reactions 
[4]. 
CCU must be distinguished from a cold-induced form of cholinergic urticaria [12]. 
This disorder should be suspected in individuals who have typical multiple small 
urticarial lesions only when exercising in the cold. Cold-induced cholinergic urticaria is 
not associated with positive cold provocation test [4]. In a small percentage of cases, 
cold urticaria is associated with the presence of a range of serum cryoproteins. The 
presence of a cryoprotein can reflect an underlying diagnosis of essential mixed 
cryoglobulinemia, hepatitis, autoimmune disease, or lymphoma [4]. Cryoproteins were 
identified in fewer than 10% of adults in a large series [11]. 
Avoidance of critical cold exposure should be recommended [3] but is often 
impossible. Symptomatic treatment of choice is the use of nsAHs [3]. In patients with 
severe CCU who continue to experience symptoms despite up-dosing of nsAHs, the 
concomitant use of leukotriene receptor antagonists or H2 blockers has been described 
[13]. Also the successful use of cyclosporin A and anti-IgE therapy in CCU has been 
reported [4, 14]. Patients with a history of anaphylaxis or systemic symptoms should 
receive an emergency kit containing an adrenaline injector, oral corticosteroid and 
antihistamine [11]. 
Omalizumab is a recombinant humanized monoclonal antibody against IgE. It is 
approved for the treatment of moderate-to-severe persistent asthma in patients with a 
positive skin test response or in vitro reactivity to a perennial aeroallergen and 
symptoms that are inadequately controlled with inhaled corticosteroids (in the Unites 
States) or inhaled corticosteroids plus a long-acting inhaled β2-agonist (in Europe) [5]. 
Omalizumab blocks the binding of IgE to the FcεRI receptor on the surface of target 
cells, including mast cells and basophils, thus reducing receptor expression and the 
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release of inflammatory mediators [15]. Four proof-of-concept trials investigated 
omalizumab in patients with chronic spontaneous urticaria who remained symptomatic 
despite antihistamine therapy [16–19]. It is known that approximately 30% to 50% of 
patients with chronic idiopathic urticaria produce IgG autoantibodies against either IgE 
or its high-affinity receptor (FcεRI) [20]. A subgroup of patients with chronic 
spontaneous urticaria exhibits IgE antibodies directed against autoantigens, such as 
thyroperoxidase [19]. All four studies showed that omalizumab significantly improved 
urticaria activity scores with rapid onset of effect which persisted for the duration of 
treatment [16–19]. A dose-finding study has demonstrated that 300 mg omalizumab 
are as efficient as 600 mg and superior to 75 mg [16]. Currently large multi-center 
phase III studies are ongoing to investigate the efficacy and safety of omalizumab in CIU 
(ClinicalTrials.gov identifier: NCT01292473). 
It has been previously shown that omalizumab treatment can be safe and effective in 
patients suffering from recalcitrant physical urticaria such as cold contact urticaria [4]. 
Also other cases of successful use of omalizumab in physical urticaria such as solar 
urticaria [21] and pressure urticaria [22] have been described. In table 2 we 
summarize those patients with cold contact urticaria treated with omalizumab. 
According to the summary of omalizumab product characteristics, the most 
commonly observed adverse reactions are injection site reactions, headache, pyrexia 
and upper abdominal pain [5]. Most of the reactions are mild or moderate in severity 
and quite rare (about 7%) [23]. Fatigue described by our patient is defined as 
uncommon adverse event (≥1/1,000 to <1/100) [5]. In general, however, omalizumab 
is well tolerated as has been learned from the use of omalizumab in large cohorts of 
adult patients [23] and children [24] suffering from allergic asthma. 
Up until now, no clear indications on possible responders of CCU patients with 
omalizumab or useful dosage and length of therapy can be given. From our 2 patients 
case 1 was responding very fast (within 1 week) and had a long-lasting improvement. 
On the other hand case 2 did not respond in a satisfactory manner and also suffered 
from a variety of side effects. However, it has to be considered that this patient also did 
not respond very well to cyclosporin A and also suffered from a broader spectrum of 
side effects with this drug. 
Conclusions 
Many case reports have already shown the beneficial effect of omalizumab in 
patients with recalcitrant physical urticaria [4, 21, 22, 25]. In addition to previously 
published reports, our case suggests that omalizumab may be an effective, rapid and 
safe treatment option in patients with cold contact urticaria who do not sufficiently 
respond to standard therapy as recommended by existing guidelines. Still there is a 
small group of patients without sufficient response to omalizumab. Further research is 
necessary to clarify the mechanism of action of omalizumab in patients with CCU. 
Future trials, including longer durations of treatment, should fully evaluate the 
potential of this agent in the treatment of all recalcitrant physical urticarias. Another 
focus of interest will be to identify the patients who will not profit from omalizumab 
treatment [8]. 
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Table 1. Classification scheme for cold contact urticaria [6] 
  
  
 Severity of reactions 
   
   
Cold urticaria type 1  reactions confined to the area of skin that came into contact with the cold 
 type 2 generalized urticaria not associated with cardiovascular or respiratory 
symptoms 
 type 3 generalized urticaria associated with cardiovascular or respiratory symptoms 
   
   
 
 
Table 2. Characteristics of cold contact urticaria patients treated with omalizumab 
        
        
Pa- 
tient 
First author, year Sex Age 
years 
Duration  
of CCU 
Previous medication Omalizumab 
dosage 
Successful 
use 
        
        
1 Boyce [4], 2006 woman 12 2 years high-dose nsAH, montelukast 375 mg/ 
2 weeks 
yes 
                2 Metz [8], 2011 man 19 NA high-dose nsAH 150 mg/ 
4 weeks 
yes 
                3 our patient – case 1, 2012 woman 53 4 months high-dose nsAH, occasional oral 
steroids  
300 mg/ 
4 weeks 
yes 
                4 our patient – case 2, 2012 woman 30 1 year high-dose nsAH 300 mg/ 
4 weeks 
no 
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